Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-12-02 in 15w | $PFE | Phase 3 | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6… NCT07029711 |
| 2026-12-02 in 15w | $PFE | Phase 3 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic… NCT06629779 |
| 2026-12-14 in 17w | $AMGN | Phase 3 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) NCT06430866 |
| 2026-12-26 in 18w | $INCY | Phase 3 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in… NCT06212999 |
| 2026-12-31 in 19w | $VIR | Phase 3 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection NCT06903338 |
| 2027-01-21 in 22w | $AMGN | Phase 3 | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2… NCT06858839 |
| 2027-01-21 in 22w | $AMGN | Phase 3 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type… NCT06858878 |
| 2027-01-25 in 23w | $VRTX | Phase 3 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in… NCT06696443 |
| 2027-02-20 in 26w | $REGN | Phase 3 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee… NCT07015905 |
| 2027-02-28 in 28w | $REGN | Phase 3 | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and… NCT07309432 |
| 2027-03-22 in 31w | $REGN | Phase 3 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult… NCT06246916 |
| 2027-04-05 in 33w | $ITCI | Phase 3 | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With… NCT05850689 |
| 2027-04-06 in 33w | $VRTX | Phase 3 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term… NCT05331183 |
| 2027-04-06 in 33w | $VRTX | Phase 3 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With… NCT07231419 |
| 2027-04-19 in 35w | $AMGN | Phase 3 | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) NCT06700343 |
| 2027-04-27 in 36w | $AMGN | Phase 3 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan… NCT06987695 |
| 2027-04-30 in 36w | $INCY | Phase 3 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6… NCT06804811 |
| 2027-05-04 in 37w | $AMGN | Phase 3 | Study to Evaluate Efficacy and Safety of Romosozumab Compared With… NCT05972551 |
| 2027-05-20 in 39w | $BIIB | Phase 3 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017… NCT03958877 |
| 2027-05-31 in 41w | $SRPT | Phase 3 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of… NCT05881408 |
| 2027-05-31 in 41w | $VRTX | Phase 3 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With… NCT06628908 |
| 2027-05-31 in 41w | $BIIB | Phase 3 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With… NCT06935357 |
| 2027-06-06 in 42w | $VRTX | Phase 3 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With… NCT05329649 |
| 2027-06-09 in 42w | $VRTX | Phase 3 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants… NCT05477563 |
| 2027-06-21 in 44w | $ITCI | Phase 3 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated… NCT06690398 |